Research landscape

CAR-T cell therapy: a cited starting point for a public research review

This snapshot surfaces the public record a team may want to inspect first. It is not a treatment recommendation, technical benchmark, market map, or conclusion about any program.

Source scope: 600 recent NLM PubMed records from 2021 through 2026 matching a CAR-T cell therapy query. Generated July 2026.

Signals in this retrieved set

SignalWhat it means
600 recent recordsA bounded public starting set, not complete coverage of every asset, trial, company, or manufacturing approach.
Adoptive immunotherapy: 528The most frequent indexed subtopic in this retrieval.
Chimeric antigen receptors: 462A frequent indexed term in the same retrieval.
Tumor microenvironment: 150A frequent indexed term in the same retrieval.

Useful first questions

Which records should be examined before a CAR-T research landscape is scoped? Where do engineering, tumor microenvironment, hematologic malignancy, and operational terms recur? Which additional trial, manufacturing, patent, regulatory, and company sources are needed for a decision-ready view?

Representative public records

PMID 42470580 · Recent public CAR-T cell therapy record.

PMID 42462103 · Recent public CAR-T cell therapy record.

PMID 42455334 · Recent public CAR-T cell therapy record.

The linked records are representative of the retrieved set. Their presence does not establish therapeutic performance, manufacturability, safety, regulatory status, or business value.

Limits

Author names are not disambiguated, counts are not citation-weighted, and the retrieval is not a systematic review. Verify every linked record and add the required trial, manufacturing, patent, regulatory, and company sources before acting.

Continue with your exact topic

Run the live preview Inspect the KOL map Request a free mini-brief